A Study on The Teratogenic Effect of Spiramycin in Albino Rats.

El-Komy, A.A.A., Abd-El-Baky, Amany E.M. and Abo-el-Ezz, Heba M.A.

Department of pharmacology, Faculty of veterinary medicine, Benha University.

ABSTRACT

Drugs or medicinal agents should only be used in pregnancy if there is proven benefit to the mother and no potential teratogenic risks. The present study was performed to evaluate the teratogenic effect of spiramycin in albino rats. The pregnant rats were divided into three groups, group (1) behaved as control received normal saline from 6th to 15th day of pregnancy. Group (2) received 150 mg/kg b.wt of spiramycin orally daily from 6th to 15th day of pregnancy. Group (3) received 300 mg/kg b.wt. of spiramycin orally daily from 6th to 15th day of pregnancy. There is no death or abortions. Treated groups showed significant decrease in weight, length and retarded growth in fetuses. Fetal resorption significantly increased. The incidences of skeletal and visceral abnormalities were increased in treated groups.

Key words: Spiramycin, Pregnancy, Abnormalities.

1. INTRODUCTION

Macrolide antibiotics are frequently used for Gram-positive lower and upper respiratory infections, Helicobacter pylori-related peptic ulcer and soft tissue infections. Moreover, for the treatment of chlamydia and other selected infections in pregnancy like Toxoplasma (Lin et al., 2013). Macrolide antibiotics are the second most frequently used antibacterial class during pregnancy (Crider et al., 2009) and (Mitchell et al., 2011). It has excellent in vitro activity which is reported for Gram-positive bacteria and mycoplasma and also for certain Gram-negative microbes such as Actinobacillus pleuropneumoniae, Pasteurella hemolytica, and Pasteurella multocida (Ose and Tonkinson, 1988).

Most therapeutic agents cross placental barrier and enter the circulation of fetus. Every drug given during pregnancy has tendency to produce some sort of structural abnormalities in the neonate (Heikkinen et al., 2000). The most incidence for malformations take place during the period of organogenesis. Drugs given during this period are more likely to induce birth defects. This critical time of fetal developments in rats and mice is from 6 - 12 days of their pregnancy (Somer, 1962). The study of abnormal prenatal development and congenital malformations caused by physical agents or exogenous chemical is a growing area of medical research in the quest for the eradication of preventable birth defects. The aim of this study was to investigate the effect
of spiramycin administration during gestation on albino rats in term of weight, length, resorption sites and detection of any gross malformations as skeletal and visceral anomalies.

2. MATERIALS AND METHODS

2.1. Animals:

The experiment was carried out on albino rats. The age and weight of used rats were 8-10 months and 210-250 gram respectively. Rats were obtained from animal house colony of faculty of Veterinary Medicine, Benha University. Rats were kept under hygienic conditions fed on standard balanced diet and water free from antimicrobials to withdraw any antibacterial residues. Female rats were examined periodically using vaginal smear technique to ensure that they were in regular estrous cycle (Heikkinen et al., 2000). Each female in estrous phase was paired with a male of proven fertility in a separate cage. In the morning, vaginal smear was taken to verify day of pregnancy. Presence of spermatozoa in the obtained vaginal smear suspected pregnancy (Somer, 1962).

2.2. Drug:

Spiramycin was manufactured by Arabcomed co., El Obour City, Cairo, Egypt under trade name (SUANO®). It is presented in a package of 100 grams spiramycin adipate, corresponding to 150 M I U spiramycin base.

3. RESULTS

The results indicated that oral administration of spiramycin in 150 mg/kg b.wt and 300 mg/kg b.wt from 6th to 15th day of pregnancy to female pregnant rats produced significant increase in number of resorbed fetuses/mother as recorded in table.

2.3. Experimental design:

The rats were classified into three groups.

Group (1): Ten Pregnant female rats were used as control group and received normal saline according to the method of administration used.

Group (2): Ten pregnant female rats were given 150 mg/kg b.wt. of spiramycin orally from 6th to 15th day of pregnancy and sacrificed at 20th day of pregnancy to detect teratogenic, histopathological effects of tested drug.

Group (3): Ten pregnant female rats were given 300mg/kg b.wt. of spiramycin orally from 6th to 15th day of pregnancy and sacrificed at 20th day of pregnancy to detect teratogenic, histopathological effects of tested drug.

2.4. Teratological design:

Pregnant female rats of the three groups were sacrificed at the 20th day of gestation and dissected to examine the effect of the administered drug on fetal development by morphological, visceral and skeletal examinations according to (Hayes, 1986).

2.5. Statistical analysis:

The data were calculated as mean ± SEM and were analyzed by using SPSS program (one way ANOVA). Differences were declared significant at $P < 0.001$.

(1). Highly significant decrease in number of fetuses table (2), fetal body weight and length of fetuses were significantly decreased (Table 3).

After oral administration of therapeutic dose of spiramycin (150 mg/kg b.wt) to pregnant rats from 6th to 15th day of pregnancy visceral examination (Table 4)
revealed: diverticulum dilation of the brain in 42.31% (figure 1), absence or hypoplasia of thymus in 30.77%, pulmonary hypoplasia in 15.38% (figure 2), cardiac enlargement in 11.54%, hepatomegaly in 23.08% and kidney hypotrophy with dilation of renal pelvis either unilateral or bilateral in 19.23%, while visceral examination of fetuses obtained from dams given orally double therapeutic dose of spiramycin (300 mg/kg b.wt) to pregnant rats from 6th to 15th day of pregnancy (Table 4) resulted in diverticulum dilation of the brain in 54.17%, absence or hypoplasia of thymus in 41.67% (figure 3), pulmonary hypoplasia in 41.67%, cardiac enlargement in 37.50%, hepatomegaly in 33.33% (figure 4) and kidney hypotrophy with dilation of renal pelvis either unilateral or bilateral in 25.0%.

Skeletal examination of fetuses obtained from mothers given orally spiramycin at dose (150 mg/kg b.wt) from 6th to 15th day of pregnancy showed impaired ossification of the skull in 59.1% (figure 5), absence of sternbra in 50%, also complete absence of 2th, 4th, 5th, or small size of sternbra. Absence of digital bone of fore (figure 5) and hind limb (figure 6) were recorded in 40.9%, absence of some metatarsal bone in 45.5% and some metacarpal bone in 40.9%, absence of caudal vertebrae in 22.7% (figure 6) of examined fetuses (table 5). The same results were obtained after oral administration of 300 mg/kg.b.wt (Table 5) (figure 7).

Table (1): Effect of spiramycin on the number of resorbed fetuses obtained from rats administered 150 and 300 mg/kg b.wt. of spiramycin orally daily from 6th to 15th day of pregnancy n=10

<table>
<thead>
<tr>
<th>Animal group</th>
<th>Number of resorbed fetuses</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group (1) control</td>
<td>0.00±0.00</td>
</tr>
<tr>
<td>Group (2)</td>
<td>0.30±0.21</td>
</tr>
<tr>
<td>Group (3)</td>
<td>0.60±0.42</td>
</tr>
</tbody>
</table>

P < 0.001

Table (2): Effect of spiramycin on the number of viable and dead fetuses obtained from rats administered 150 and 300 mg/kg b.wt of spiramycin orally daily from 6th to 15th day of pregnancy. (n=10)

<table>
<thead>
<tr>
<th>Animal group</th>
<th>Number of fetus</th>
<th>Number of viable fetuses</th>
<th>Number of dead fetuses</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>10.0±0.394</td>
<td>10.0±0.394</td>
<td>-</td>
</tr>
<tr>
<td>Group (2)</td>
<td>6.80±0.416</td>
<td>6.80±0.416</td>
<td>-</td>
</tr>
<tr>
<td>Group (3)</td>
<td>3.40±0.37</td>
<td>3.40±0.37</td>
<td>-</td>
</tr>
</tbody>
</table>
A Study on The Teratogenic Effect of Spiramycin in Albino Rats.

Table (3): Effect of spiramycin on body weight and length of fetus obtained from rats administered 150 and 300mg/kg b.wt of spiramycin orally daily from 6th to 15th day of pregnancy. n=10

<table>
<thead>
<tr>
<th>Animal group</th>
<th>Fetal body length (cm)</th>
<th>Fetal body weight (gm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group (1) Control</td>
<td>4.513±0.09</td>
<td>4.226±0.09</td>
</tr>
<tr>
<td>Group (2)</td>
<td>3.348±0.09***</td>
<td>3.427±0.07***</td>
</tr>
<tr>
<td>Group (3)</td>
<td>2.568±0.10***</td>
<td>2.625±0.10***</td>
</tr>
</tbody>
</table>

Table (4): Visceral abnormalities in fetuses obtained from rats administered spiramycin (150 mg and 300 mg/kg b.wt orally, once daily from 6th to 15th day of pregnancy.

<table>
<thead>
<tr>
<th>Abnormalities in</th>
<th>Spiramycin (150 mg / kg b.wt)</th>
<th>(n=26)</th>
<th>Spiramycin (300 mg/kg b.wt)</th>
<th>(n=24)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brain</td>
<td>42.31%</td>
<td></td>
<td>54.17%</td>
<td></td>
</tr>
<tr>
<td>Thymus</td>
<td>30.77%</td>
<td></td>
<td>41.67%</td>
<td></td>
</tr>
<tr>
<td>Heart</td>
<td>11.54%</td>
<td></td>
<td>37.50%</td>
<td></td>
</tr>
<tr>
<td>Lungs</td>
<td>15.38%</td>
<td></td>
<td>41.67%</td>
<td></td>
</tr>
<tr>
<td>Liver</td>
<td>23.08%</td>
<td></td>
<td>33.33%</td>
<td></td>
</tr>
<tr>
<td>Kidney</td>
<td>19.23%</td>
<td></td>
<td>25.0%</td>
<td></td>
</tr>
</tbody>
</table>

Table (5): Skeletal abnormalities in fetuses obtained from rats administered spiramycin (150 mg and 300 mg/kg b.wt orally, once daily from 6th to 15th day of pregnancy.

<table>
<thead>
<tr>
<th>Abnormalities in</th>
<th>Spiramycin (150mg / kg b.wt)</th>
<th>(n=22)</th>
<th>Spiramycin (300mg/kg b.wt)</th>
<th>(n=26)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Skull</td>
<td>59.1%</td>
<td></td>
<td>61.5%</td>
<td></td>
</tr>
<tr>
<td>Sternum</td>
<td>50.0 %</td>
<td></td>
<td>53.8%</td>
<td></td>
</tr>
<tr>
<td>Ribs</td>
<td>-</td>
<td></td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Digital bone</td>
<td>40.9%</td>
<td></td>
<td>50%</td>
<td></td>
</tr>
<tr>
<td>Metatarsal bone</td>
<td>45.5%</td>
<td></td>
<td>46.2%</td>
<td></td>
</tr>
<tr>
<td>Metacarpal bone</td>
<td>40.9%</td>
<td></td>
<td>53.8%</td>
<td></td>
</tr>
<tr>
<td>Caudal vertebrae</td>
<td>22.7%</td>
<td></td>
<td>38.09%</td>
<td></td>
</tr>
</tbody>
</table>
Figure (1): Diverticulum dilatation (d) of brain in a fetus obtained from rat administered therapeutic dose of spiramycin (150 mg/kg/b.wt.) orally once daily from 6th to 15th day of gestation. C: Control Fetus T: Tested Fetus

Figure (2): Pulmonary Hypoplasia (H) and cardiac enlargement (E) in a fetus obtained from rat administered therapeutic dose of spiramycin (150 mg/kg/b.wt.) orally once daily from 6th to 15th day of gestation. C: Control Fetus T: Tested Fetus

Figure (3): Thymus Hypoplasia (T) in a fetus obtained from rat administered therapeutic dose of spiramycin (300 mg/kg/b.wt.) orally once daily from 6th to 15th day of gestation. C: Control Fetus T: Tested Fetus
Figure (4): Hepatomegaly (M) in a fetus obtained from rat administered therapeutic dose of spiramycin (300 mg/kg/b.wt.) orally once daily from 6th to 15th day of gestation.
C: Control Fetus T: Tested Fetus

Figure (5): Incomplete ossification (O) of the skull and absence of digital bones (A) of fetus obtained from rat administered spiramycin (150 mg/b.wt) orally, once daily from 6th to 15th day of gestation (n=10).
C: Control fetus T: Treated fetus
Figure (6): Complete absence of caudal vertebrae (C) and absence of some digital bones (D) in a fetus obtained from rat administered spiramycin daily orally (150 mg/kg b.wt.) from 6th to 15th day of gestation.

C: Control fetus  T: Treated fetus

Figure (7): Complete absence of caudal vertebrae (C) and digital bones (D) in a fetus obtained from rat administered spiramycin daily orally (300 mg/kg b.wt.) from 6th to 15th day of gestation.

C: Control fetus  T: Treated fetus

4. DISCUSSION

Oral administration of spiramycin by using stomach tube in therapeutic and double therapeutic doses (150 and 300 mg/kg b.wt) to female pregnant rats induced marked and significant decrease in the number of feti/mother when compared with that of the control group without any fetal deaths. The decrease in the number of feti/mother might be attributed to the direct toxic action of the tested drug on the early developed fertilized
ovum or the lack of oval production or of the basic cell constituent by the mother (Tuchmann-Duplessis, 1975). Spiramycin in therapeutic and double therapeutic doses resulted in marked increase in the number of resorbed feti either early or late. This result was similar to that reported by (El-Sayed et al., 2014) The increase in the number of resorbed fetuses in the present study might be attributed to the interference of the tested drug with the placental transmission of leucin amino acid and magnesium as deficiency of leucin or magnesium produced high incidence of fetal resorptions (Tuchmann-Duplessis, 1975). Administration of spiramycin in therapeutic and double therapeutic dose to female pregnant rats during the period of organogenesis produced significant decrease in both weight and length of fetuses. This result was consistent with that reported by (Karabulut et al., 2008). There was significant decrease in all growth and developmental parameters following administration of macrolides in cultured rat embryos dose dependently. The recorded reduction in fetal weight and length which resulted after oral administration of tested drug might be attributed to the disturbance in metabolism of some minerals as magnesium and zinc in fetus, or to the interference of the drug to the placental transmission of magnesium and zinc from the mother to the fetus (Tuchmann-Duplessis, 1975) as deficiencies of magnesium and zinc induced retardation of fetal growth, increasing fetal resorption and high rate of embryonic death.

Administration of therapeutic and double therapeutic doses of spiramycin to female pregnant rats during the period of organogenesis caused many fetal visceral abnormalities as diverticulum dilatation in the brain of fetuses. The obtained result was consistent with those reported by (Karabulut et al., 2008). Also another study (Moriyama et al., 2011) concluded that treatment with rapamycin induced enormous influences on early developmental period. This lesion might be attributed to the transfusion of arginine amino acid caused by this drug or to the disturbance of the metabolism of arginine in fetus (Tuchmann-Duplessis, 1975) proved that, deficiency of arginine in pregnant rat or mice resulted in brain abnormalities such as diverticulum dilatation due to inhibition of cell differentiation. Spiramycin in the therapeutic and double therapeutic dose resulted in hypoplasia of thymus gland, which was a dose-dependent. This result was similar to that reported by (Jordan and Higdon, 1988). Administration of tilmicosin to rats induced both total visceral and skeletal anomalies and with (Petrova and Savitskaia, 1988) following administration of oleandomycin in rats. (Takai et al., 1990) recorded that; tacrolimus might impair thymic microenvironment and disturb the thymocyte maturation. Other investigators as (Moriyama et al., 2011), mentioned that rapamycin induced enormous influences on early developmental period. Administration of spiramycin in therapeutic and double therapeutic dose to female pregnant rats produced cardiac hyperplasia which was a dose-dependent. These fetal abnormalities similar to that reported by (Jordan and Bernard, 1989) following administration of tilmicosin to female rats and by (Otterblad and Danielsson, 2005) reported that erythromycin induced congenital malformation.

Administration of spiramycin in therapeutic and double therapeutic dose to female pregnant rats from 6th to 15th day of pregnancy induced pulmonary hypoplasia which was dose-dependent. Similar results were obtained by (Karabulut et al., 2008), reported that, there was significant decrease in all growth and developmental parameters following administration of macrolides in cultured rat embryos dose dependently.
Administration of spiramycin produced hepatomegaly. This result agrees with (Jordan and Higdon, 1988). Administration of tilmicosin to rats induced both total visceral and skeletal anomalies. Administration of spiramycin in therapeutic and double therapeutic dose to female pregnant rats induced hypoplasia of one or both kidneys with unilateral or bilateral dilatation of renal pelvis. This result was dose-dependent. The same result was recorded by (Nielson et al., 1995) following administration of tacrolimus to pregnant rats. Administration of spiramycin in therapeutic and double therapeutic dose produced some fetal skeletal malformations such as impaired ossification of skull, absence of sternbrae, reduction or absence of caudal vertebrae, absence of digit's bone of fore and hind limb and absence of some metacarpal and metatarsal bone. This result agree with that reported by many investigators as (Phornphutkul et al., 2009) and (Noda, 1993). The reported bone lesion might be attributed to deficiency of functionally available magnesium. (Menschik et al., 1997).

5. CONCLUSION
Administration of spiramycin during period of organogenesis especially at high dose induced some fetal defects and abnormalities, so it is advisable to avoid using during pregnancy.

6. REFERENCES

http://dx.doi.org/10.1001/archpediatrics.2009.188


A Study on The Teratogenic Effect of Spiramycin in Albino Rats.

http://dx.doi.org/10.1016/j.ajog.2012.12.023


Noda, A. (1993): Teratogenicity study of EL-870 (tilmicosin aqueous) in rabbits by gavage. Unpublished study No. 91-001 from Research Institute for Animal Science in Biochemistry and Toxicology, Japan. Submitted to WHO by Lilly, Basingstoke, UK.


Tuchmann-Duplessis, (1975): Drug effect on the fetus. ADIS press, New York, USA.